Glatiramer is an immunomodulator that reduces the frequency of multiple sclerosis (MS) recurrences and prevents the risk of disability. Depending on the dose that the patient needs, Glatiramer will be injected once a day or 3 times a week, each time at least 48 hours apart.

According to a study published in Lancet Oncology, the combination of ramucirumab and pembrolizumab showed good tolerability in phase I trials for several malignancies such as gastric adenocarcinoma and gastric junction cancer. Esophageal.

With multiple myeloma, your immune system is severely affected, which reduces your ability to fight off infections. Therefore, modern multiple myeloma treatments focus on the immune system. New drugs for multiple myeloma target the natural features of the immune system's ability to fight disease. Currently, there are many immunotherapy drugs that your doctor can use to treat you. Let's learn new knowledge about immunotherapy drugs for multiple myeloma with Vinmec in the article below.

Positive treatment results when using the immunotherapy drug Pembrolizumab (Keytruda) are encouraging signs for cancer patients, especially those with late-stage, metastatic cancer.